ACELYRIN(US:SLRN)2023-11-11 20:11Financial Highlights - Cash, cash equivalents, and short-term marketable securities totaled $788.4 million as of September 30, 2023[7] - Research and development expenses were $74.6 million for the third quarter of 2023, compared to $12.5 million for the same period in 2022[8] - General and administrative expenses were $19.9 million for the third quarter of 2023, compared to $2.9 million for the same period in 2022[8] - Net loss totaled $83.9 million for the third quarter of 2023, or $0.87 per share, compared to $14.4 million, or $8.17 per share, for the third quarter of 2022[8] - Total assets were $800.489 million as of September 30, 2023, compared to $319.923 million as of December 31, 2022[6] Clinical Program Updates - Top-line data from the global Phase 2b/3 trial for izokibep in PsA and proof-of-concept data for lonigutamab in thyroid eye disease are expected in the first quarter of 2024[7] - 46-week results from a Phase 2 trial of izokibep in PsA showed >75% achievement of ACR50, >50% achievement of ACR70, >70% achievement of PASI100, >80% resolution of enthesitis, and >50% achievement of Minimal Disease Activity (MDA)[7] - Approximately 25% of patients achieved HiSCR100 responses within 12 weeks in hidradenitis suppurativa trial[7] Leadership and Corporate Updates - Patricia Turney joined as Chief Technical Operations Officer[2] - Shephard (Shep) Mpofu joined as Senior Vice President of Development[7]